{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:47:23Z","timestamp":1768513643852,"version":"3.49.0"},"reference-count":66,"publisher":"Georg Thieme Verlag KG","issue":"09","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Der irreversible Monoaminoxidase-Hemmer Tranylcypromin ist seit mehr als 60\n                    Jahren als Antidepressivum bekannt. Ziel dieses \u00dcbersichtsartikels ist\n                    die Bestimmung des Standes der Wissenschaft und Therapie von Tranylcypromin.\n                    Daf\u00fcr wird die aktuelle Fachliteratur ausgewertet und hinsichtlich\n                    gegenw\u00e4rtiger Schwerpunkte und allgemeiner Trends der praktischen\n                    Psychopharmakotherapie eingeordnet. Im Ergebnis kann Tranylcypromin heute durch\n                    neue Metaanalysen kontrollierter Studien als gut etabliert f\u00fcr die\n                    Behandlung der therapieresistenten Depression gelten. Die Dosierung\n                    (Maximaldosis, Erhaltungsdosis) wird zunehmend f\u00fcr Anforderungen der\n                    therapieresistenten Depression angepasst. Die Monoaminoxidase ist nicht nur\n                    prim\u00e4re pharmakologische Zielstruktur von Tranylcypromin sondern\n                    bestimmt zu Therapiebeginn als arzneistoffmetabolisierendes Enzym\n                    enantioselektiv auch die Pharmakokinetik des Monoaminoxidase-Hemmers. Mit\n                    zunehmender Diversit\u00e4t der antidepressiven Pharmakotherapie ist eine\n                    fortw\u00e4hrende Zuordnung von Tranylcypromin als therapeutische\n                    \u201eultima ratio\u201c bei Depression \u00fcberdenkenswert. Es wird\n                    geschlussfolgert, dass Tranylcypromin als Mittel der zweiten Wahl eine wertvolle\n                    Option der antidepressiven Therapie bleibt. Die Kriterien f\u00fcr eine\n                    Umstellung von anderen Antidepressiva auf den Monoaminoxidase-Hemmer\n                    m\u00fcssen noch besser definiert werden.<\/jats:p>","DOI":"10.1055\/a-2182-5365","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T18:53:31Z","timestamp":1700592811000},"page":"352-363","source":"Crossref","is-referenced-by-count":1,"title":["Psychopharmakotherapie mit dem MAO-Hemmer Tranylcypromin Schwerpunkte\n                    und Trends aus Theorie und Praxis"],"prefix":"10.1055","volume":"93","author":[{"given":"Sven","family":"Ulrich","sequence":"additional","affiliation":[{"name":"Med.-wiss. Abt., Aristo Pharma GmbH, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Lewitzka","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie,\n                    Universit\u00e4tsklinikum Carl Gustav Carus, Dresden, Deutschland, Dresden,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0893-133X(94)00058-8","article-title":"MAOIs in the contemporary treatment of depression","volume":"12","author":"M E Thase","year":"1995","journal-title":"Neuropsychopharmacol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.euroneuro.2017.05.007","article-title":"Tranylcypromine in mind (Part I): Review of pharmacology","volume":"27","author":"S Ulrich","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref3","first-page":"1","article-title":"The prescriber\u2019s guide to classic MAO inhibitors (phenelzine,\n                    tranylcypromine, isocarboxazid) for treatment-resistant depression","volume":"15","author":"V Van den Eynde","year":"2022","journal-title":"CNS Spectr"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5414\/CP204169","article-title":"Insufficient recovery of monoamine oxidase in a bioequivalence study of the\n                    monoamine oxidase inhibitor tranylcypromine: Recommendation of the\n                    tranylcypromine enantiomer test","volume":"60","author":"S Ulrich","year":"2022","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/jamapsychiatry.2019.0044","article-title":"Monoamine oxidase B total distribution volume in the prefrontal cortex of major\n                    depressive disorder: An [11C]-SL25.1188 PET study","volume":"76","author":"S Moriguchi","year":"2019","journal-title":"JAMA Psychiat"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0447.2007.01121.x","article-title":"Is MAO-B activity in platelets associated with the occurrence of suicidality and\n                    behavioural personality traits in depressed patients?","volume":"117","author":"U Lewitzka","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(88)90033-9","article-title":"Neurochemical changes in rat brain amines after short- and long-term inhibition\n                    of monoamine oxidase by a low dose of tranylcypromine","volume":"23","author":"D R Hampson","year":"1988","journal-title":"Biol Psychiat"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/0006-3223(89)90289-8","article-title":"Chronic effects of tranylcypromine and 4-fluorotranylcypromine on regional brain\n                    monoamine metabolism in rats: A comparison with clorgyline","volume":"25","author":"A J Greenshaw","year":"1989","journal-title":"Biol Psychiat"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3349\/ymj.1993.34.3.266","article-title":"Regional differences in the levels of biogenic amines and their metabolites in\n                    rat brain after tricyclic antidepressant treatments","volume":"34","author":"M Y Chung","year":"1993","journal-title":"Yonsei Med J"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0022-3565(25)23665-5","article-title":"Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of\n                    monoamine oxidase type A","volume":"248","author":"M Da Prada","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"ref11","first-page":"9","article-title":"The neurochemical profile of long term oral administration of moclobemide","volume":"11","author":"D J Haleem","year":"1998","journal-title":"Pak J Pharm Sci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00431629","article-title":"Neurochemical characterization of a new potent and selective serotonin uptake\n                    inhibitor: Lu 10-171","volume":"51","author":"J Hyttel","year":"1977","journal-title":"Psychopharmacology (Berl)"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euroneuro.2017.04.003","article-title":"Tranylcypromine in mind (Part II): Review of clinical pharmacology and\n                    meta-analysis of controlled studies in depression","volume":"27","author":"R Ricken","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref14","first-page":"281","volume-title":"Antidepressiva. In: Ammon HPT, Hrsg. Arzneimittelneben- und\n                    -wechselwirkungen","author":"E J Verspohl","year":"1991"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1073\/pnas.87.19.7522","article-title":"Chronic antidepressant administration decreases the expression of tyrosine\n                    hydroxylase in the rat locus coeruleus","volume":"87","author":"E J Nestler","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jad.2020.03.022","article-title":"Antidepressants of different classes cause distinct behavioral and brain pro-\n                    and anti-inflammatory changes in mice submitted to an inflammatory model of\n                    depression","volume":"268","author":"V S Tomaz","year":"2020","journal-title":"J Affect Disord"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0014-2999(00)00706-8","article-title":"Monoamine oxidase inhibitors reduce conditioned fear stress-induced freezing\n                    behavior in rats","volume":"406","author":"Y Maki","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"ref18","first-page":"259","article-title":"Metaanalyse kontrollierter Studien von Tranylcypromin bei Depression und\n                    Bewertung der Qualit\u00e4t des Studiendesigns","volume":"24","author":"S Ulrich","year":"2017","journal-title":"Psychopharmakother"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1176\/ajp.2007.164.3.524","article-title":"Treatment with low doses of tranylcypromine resulted in a disappointing\n                    remission rate","volume":"164","author":"W A Nolen","year":"2007","journal-title":"Am J Psychiat"},{"key":"ref20","first-page":"211","article-title":"Das Problem der Heterogenit\u00e4t zwischen in den USA und nicht in den USA\n                    durchgef\u00fchrten Antidepressivastudien","volume":"21","author":"H J M\u00f6ller","year":"2014","journal-title":"Psychopharmakother"},{"key":"ref21","first-page":"105","volume-title":"Einsatz von Antidepressiva bei therapieresistenten Depressionen. In: Bauer M,\n                    Bergh\u00f6fer A, Brakemeier EL, Adli M, Hrsg. Therapieresistenz bei\n                    Depressionen und bipolaren St\u00f6rungen","author":"I G Anghelescu","year":"2022"},{"key":"ref22","first-page":"299","volume-title":"Antidepressiva. In: Kasper S, Volz HP, Hrsg. Psychiatrie und Psychotherapie\n                    compact: Das gesamte Facharztwissen","author":"H P Volz","year":"2008"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JCP.0000000000001153","article-title":"Efficacy and adverse effects of tranylcypromine and tricyclic antidepressants in\n                    the treatment of depression: A systematic review and comprehensive\n                    meta-analysis","volume":"40","author":"S Ulrich","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"ref24","first-page":"700","article-title":"Die Behandlung psychotischer Antriebst\u00f6rungen","volume":"118","author":"E Langner","year":"1968","journal-title":"Wien Med Wochenschr"},{"key":"ref25","first-page":"66","article-title":"Adjuvantes Tranylcypromin mit Antipsychotika der zweiten Generation in der\n                    Behandlung schizophrener Negativsymptomatik: Retrospektive Studie zur\n                    Therapieroutine von 53 Patienten und Kurz\u00fcbersicht zur Literatur","volume":"18","author":"D Roesch-Ely","year":"2011","journal-title":"Psychopharmakother"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1080\/03007995.2021.1895095","article-title":"Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for\n                    the treatment of schizophrenia with predominant negative symptoms: A restoration\n                    of evidence","volume":"37","author":"S Ulrich","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/JCP.0000000000000409","article-title":"Efficacy of tranylcypromine in bipolar depression: A systematic review","volume":"35","author":"W T Heijnen","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"ref28","first-page":"64","article-title":"Revisiting the effectiveness of standard antidepressants in bipolar disorder:\n                    Are monoamine oxidase inhibitors superior?","volume":"42","author":"A G Mallinger","year":"2009","journal-title":"Psychopharmacol Bull"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bdi.12780","article-title":"Stepwise treatment of acute bipolar depression","volume":"21","author":"G Parker","year":"2019","journal-title":"Bipolar Disord"},{"key":"ref30","first-page":"139","article-title":"A Brazilian case of treatment-resistant generalized anxiety disorder\n                    successfully treated with monoamine oxidase inhibitor (MAOI)","volume":"32","author":"CG F Faria","year":"2020","journal-title":"Psychiatr Danub"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1055\/s-0030-1248499","article-title":"Tranylcypromin bei chronifizierter therapieresistenter Agoraphobie mit\n                    Panikst\u00f6rung und rezidivierender depressiver St\u00f6rung","volume":"37","author":"R F B\u00f6rner","year":"2010","journal-title":"Psych Prax"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-198808000-00008","article-title":"Tranylcypromine in social phobia","volume":"8","author":"M Versiani","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"ref33","first-page":"241","article-title":"Differential response to antidepressant drugs in outpatients affected by anxiety\n                    or depressive disorders and scoring high on the scales 1 and 3 of the\n                    MMPI-2","volume":"32","author":"A Picardi","year":"1997","journal-title":"Riv Psich"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.psychres.2008.06.025","article-title":"Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with\n                    panic disorder comorbid with social anxiety disorder","volume":"175","author":"A E Nardi","year":"2010","journal-title":"Psychiatry Res"},{"key":"ref35","first-page":"160","article-title":"Three evaluations of monoamine oxidase inhibitor and phenothiazine\n                    combination","volume":"26","author":"N W Winkelman","year":"1965","journal-title":"Dis Nerv Syst"},{"key":"ref36","first-page":"70","article-title":"Monoaminoxidase-Hemmer in der Behandlung von Zwangserkrankungen","volume":"64","author":"A Erfurth","year":"1993","journal-title":"Nervenarzt"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2011.20.1.1","article-title":"MAO-inhibitors in Parkinson\u2019s disease","volume":"20","author":"P Riederer","year":"2011","journal-title":"Exp Neurobiol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/070674376200701S18","article-title":"Tranylcypromine and the extrapyramidal syndromes","volume":"7","author":"A Barbeau","year":"1962","journal-title":"Can Psychiatr Assoc J"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/014107688107400905","article-title":"Tranylcypromine isomers and Parkinson\u031bs disease: New aspects of an old drug","volume":"74","author":"G P Reynolds","year":"1981","journal-title":"J R Soc Med"},{"key":"ref40","first-page":"49","article-title":"Antidepressiva-Therapie bei Morbus Parkinson","volume":"29","author":"G Laux","year":"2022","journal-title":"Psychopharmakother"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1055\/s-0028-1083819","article-title":"Safety of high-intensity treatment with the irreversible monoamine oxidase\n                    inhibitor tranylcypromine in patients with treatment-resistant depression","volume":"41","author":"M Adli","year":"2008","journal-title":"Pharmacopsychiat"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/JCP.0000000000000945","article-title":"Tranylcypromine plus amitriptyline for electroconvulsive therapy-resistant\n                    depression: A long-term study","volume":"38","author":"R Ferreira-Garcia","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jad.2019.03.028","article-title":"Relative effectiveness of tricyclic antidepressant versus monoamine oxidase\n                    inhibitor monotherapy for treatment-resistant depression","volume":"250","author":"T Kim","year":"2019","journal-title":"J Affect Disord"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40263-021-00837-6","article-title":"Cardiovascular effects of combining subcutaneous or intravenous esketamine and\n                    the MAO inhibitor tranylcypromine for the treatment of depression: A\n                    retrospective cohort study","volume":"35","author":"V M Ludwig","year":"2021","journal-title":"CNS Drugs"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1055\/s-0043-105516","article-title":"Der hypertensive Notfall","volume":"142","author":"G B\u00f6nner","year":"2017","journal-title":"Dtsch Med Wochenschr"},{"key":"ref47","first-page":"6","article-title":"Unerw\u00fcnschte Wirkungen von Antidepressiva in der Routinebehandlung","volume":"1","author":"L G Schmidt","year":"1994","journal-title":"Psychopharmakother"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00702-018-1932-y","article-title":"A reassessment of the safety profile of monoamine oxidase inhibitors:\n                    Elucidating tired old tyramine myths","volume":"125","author":"P K Gillman","year":"2018","journal-title":"J Neural Transm (Vienna)"},{"key":"ref49","first-page":"73","article-title":"The prescriber\u2019s guide to the MAOI diet \u2013 thinking through\n                    tyramine troubles","volume":"52","author":"V Van den Eynde","year":"2022","journal-title":"Psychopharmacol Bull"},{"key":"ref50","first-page":"96","article-title":"Verordnung von Neuro-Psychopharmaka","volume":"30","author":"J Fritze","year":"2023","journal-title":"Psychopharmakother"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-021-00832-x","article-title":"Monoamine oxidase inhibitors (MAOIs) in psychiatric practice: How to use them\n                    safely and effectively","volume":"35","author":"S R Chamberlain","year":"2021","journal-title":"CNS Drugs"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s40263-013-0097-3","article-title":"Current place of monoamine oxidase inhibitors in the treatment of\n                    depression","volume":"27","author":"K I Shulman","year":"2013","journal-title":"CNS Drugs"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jad.2021.01.021","article-title":"Revisiting monoamine oxidase inhibitors for the treatment of depressive\n                    disorders: A systematic review and network meta-analysis","volume":"282","author":"R Suchting","year":"2021","journal-title":"J Affect Disord"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/JCP.0000000000001498","article-title":"60 Years of combining tranylcypromine: A systematic review of available\n                    evidence","volume":"42","author":"E Wagner","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/phar.1576","article-title":"Combination therapy with monoamine oxidase inhibitors and other antidepressants\n                    or stimulants: Strategies for the management of treatment-resistant\n                    depression","volume":"35","author":"S J Thomas","year":"2015","journal-title":"Pharmacother"},{"key":"ref56","first-page":"50","article-title":"Moving on with monoamine oxidase inhibitors","volume":"19","author":"J A Bodkin","year":"2021","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology:\n                    Update 2017","volume":"51","author":"C Hiemke","year":"2018","journal-title":"Pharmacopsychiat"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/JCP.0000000000001452","article-title":"Combination of tranylcypromine and mirtazapine in difficult-to-treat\n                    depression","volume":"41","author":"E Kavakbasi","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/JCP.0000000000001130","article-title":"Relative effectiveness of monoamine oxidase inhibitor and tricyclic\n                    antidepressant combination therapy for treatment-resistant depression","volume":"39","author":"J D Amsterdam","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"ref60","first-page":"a1326","article-title":"Gelijktijdig gebruik van tranylcypromine en trazodon kann leiden tot het\n                    serotoninesyndroom","volume":"7","author":"F Van Hunsel","year":"2013","journal-title":"Pharm Weekbl Wetenschappelijk Platform"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1023\/A:1006901900106","article-title":"Metabolism of monoamine oxidase inhibitors","volume":"19","author":"G B Baker","year":"1999","journal-title":"Cell Mol Neurobiol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1592\/phco.24.14.1295.43156","article-title":"Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: A\n                    potent, selective, and irreversible monoamine oxidase type B inhibitor","volume":"24","author":"J J Th\u00e9bault","year":"2004","journal-title":"Pharmacother"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-2007-1014361","article-title":"Double-blind comparison of moclobemide and tranylcypromine in depression","volume":"26","author":"G Heinze","year":"1993","journal-title":"Pharmacopsychiat"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/0006-2952(76)90071-X","article-title":"Effects of iproniazid and tranylcypromine on the half-life of\n                    N,N-dimethyltryptamine in rat brain and liver","volume":"25","author":"Lu LJ Wang","year":"1976","journal-title":"Biochem Pharmacol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1040217","DOI":"10.3389\/fpsyt.2022.1040217","article-title":"Therapeutic use of psilocybin: Practical considerations for dosing and\n                    administration","volume":"13","author":"C A MacCallum","year":"2022","journal-title":"Front Psychiat"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1017\/S1092852919001196","article-title":"Revitalizing monoamine oxidase inhibitors: A call for action","volume":"25","author":"P K Gillman","year":"2020","journal-title":"CNS Spectrums"},{"key":"ref67","first-page":"24","article-title":"Behandlung therapieresistenter Depression nach Non-Response auf\n                    Tranylcypromin","volume":"26","author":"S Ulrich","year":"2019","journal-title":"Psychopharmakother"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2182-5365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:40:40Z","timestamp":1757544040000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2182-5365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":66,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2025,9,10]]},"published-print":{"date-parts":[[2025,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2182-5365","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]}}}